Lung Cancer | Specialty

Maintenance Therapy in Non-Small Cell Lung Cancer

February 7th 2014

Optimizing Maintenance Therapy in NSCLC

February 7th 2014

Adjuvant EGFR Inhibition in Patients With NSCLC

February 7th 2014

Next-Generation Targeted Therapies in NSCLC

February 7th 2014

Development of ALK Inhibitors in Advanced NSCLC

February 7th 2014

Second-Generation ALK Inhibitors in NSCLC

February 7th 2014

Current Status of Immunotherapy in NSCLC

February 7th 2014

Immune Checkpoint Inhibitor Combinations in NSCLC

February 7th 2014

Checkpoint Inhibitor Related Pseudoprogression in NSCLC

February 7th 2014

Introduction: Checkpoint Inhibition in NSCLC

February 7th 2014

Anti-PD-1 Antibody MK-3475 Advances Into Multiple Tumor Types

February 7th 2014

Merck announced the signing of three separate clinical collaboration agreements to evaluate the potential of its investigational anti-PD-1 immunotherapy MK-3475 across multiple tumor types

Dr. Herbst on the Benefit of Targeting PD-1/PD-L1

February 4th 2014

Roy S. Herbst, MD, PhD, a professor of medicine at the Yale Cancer Center and chief of medical oncology at Smilow Cancer Hospital at Yale-New Haven in Connecticut, discusses the unique benefit of targeting the PD-1/PD-L1 pathway in lung cancer.

Clinical Trial Changes Needed to Improve Outcomes in Stage III NSCLC

February 4th 2014

Treatment of stage III non-small cell lung cancer (NSCLC) with chemotherapy, radiation, and surgery has hit a plateau, and the key to improved outcomes will hinge on the testing of targeted therapies in clinical trials with more novel designs and better patient selection, according to a leading researcher.

The Role of Anti-PD-L1 Immunotherapy in Cancer

January 29th 2014

Immunotherapy has become an increasingly appealing therapeutic strategy for patients with cancer, with many late-stage clinical trials demonstrating overall survival (OS) advantages in melanoma and castrationresistant prostate cancer.

Dr. Rapoport Describes Samsca's Mechanism of Action

January 21st 2014

Frederick Alan Rapoport, MD, clinical instructor in the Department of Medicine at NYU Langone Medical Center, describes the mechanism and utility of Samsca (tolvaptan).

Kris Provides Insight Into New Drugs for Lung Cancer

January 16th 2014

Mark G. Kris, MD, from the Memorial Sloan-Kettering Cancer Center, describes the new drugs and other emerging trends in lung cancer.

Dr. Piperdi on Immunotherapy in Lung Cancer

January 15th 2014

Bilal Piperdi, MD, Associate Professor of Clinical Medicine, Department of Medicine (Oncology), Albert Einstein College of Medicine, discusses the potential of immunotherapy for the treatment of patients with lung cancer.

Dabrafenib Receives Breakthrough Designation for NSCLC

January 13th 2014

The BRAF inhibitor dabrafenib (Tafinlar) has received a Breakthrough Therapy designation from the FDA for its potential as a treatment for patients with metastatic BRAF V600E mutation-positive non-small cell lung cancer (NSCLC) who have received at least one prior line of platinum-containing chemotherapy.

Dr. Kris on the Challenges of Treating Lung Cancer

January 13th 2014

Mark G. Kris, MD, William and Joy Ruane Chair in Thoracic Oncology, Memorial Sloan Kettering Cancer Center, discusses some of the challenges of treating patients with lung cancer.

"N of 1" Research: Molecular Findings Create Urgency for New Drug Discovery Paradigm

January 13th 2014

There has been considerable discussion within the oncology literature during the past several years regarding the level of evidence required to consider a new antineoplastic agent an acceptable "standard-of-care" in routine disease management.